Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for bleeding disorders, including its lead candidate sutacimig currently in Phase 3 trials. The company remains pre-revenue, incurring significant operating losses as it advances its clinical pipeline, and anticipates the need for substantial additional funding to support its research and development programs.
Hemab Therapeutics reported financial results for the third quarter of 2026 and provided a corporate update on its clinical pipeline. The company transitioned to a late-stage biotech by initiating the SOLARA Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia and dosing the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding.
Term
Q3 2026
“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”
Benny Sørensen, MD, PhD, CEO of Hemab
“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”
Hemab Therapeutics Holdings, Inc. has appointed Keli Walbert to its Board of Directors and Audit Committee, effective September 24, 2026. Ms. Walbert will receive an annual cash retainer of $40,000 for board service plus $10,000 for committee service, along with an initial grant of options to purchase 36,000 shares of common stock vesting over three years. This appointment fills a Class I director seat with a term expiring at the 2027 annual meeting.